Table 3.
Reduction protocol for low-potency drugs
| Generic name | Product name | Maximum reduction rate † (mg/week) | Maximum reduction ‡ (mg) |
|---|---|---|---|
| Sulpiride |
Dogmatyl, others |
50 |
100 |
| Sultopride |
Barnetil |
50 |
100 |
| Pipamperone |
Propitan |
50 |
100 |
| Chlorpromazine |
Contomin, others |
25 |
50 |
| Levomepromazine |
Levotomin, others |
25 |
50 |
| Carpiprammine |
Defecton |
25 |
50 |
| Oxypertine |
Forit |
20 |
40 |
| Zotepine |
Lodopin, others |
16.5 |
33 |
| Quetiapine |
Seroquel |
16.5 |
33 |
| Clocapramine |
Clofekton |
10 |
20 |
| Mosapramine |
Cremin |
8.25 |
16.5 |
| Propericiazine |
Neuleptil |
5 |
10 |
| Prochlorperazine |
Novamin |
3.75 |
7.5 |
| Moperone | Luvatren | 3.125 | 6.25 |
†Maximum reduction rate represents the maximum acceptable reduction per week.
‡Maximum reduction represents the maximum amount of reduction at a time. After maximum reduction, subsequent reduction is performed after a minimum 2-week observation period.
(Cited and partially modified from Sukegawa [11]).